Literature DB >> 26714181

Developments in the diagnostic procedures for von Willebrand disease.

A De Jong1, J Eikenboom1.   

Abstract

Von Willebrand disease (VWD) is the most common inherited bleeding disorder but its diagnosis can be challenging due to the heterogeneity of the disease. VWD is mainly associated with mild mucocutaneous bleeding, although there are more severe phenotypes with bleeding from the gastrointestinal tract or even the joints. Also, surgical interventions and trauma may lead to critical bleeding events. These bleeding episodes are all related to quantitative or qualitative defects of von Willebrand factor (VWF), a multimeric glycoprotein produced by endothelial cells and megakaryocytes, which mediates platelet adhesion and aggregation and binds factor VIII (FVIII) in the circulation. This review describes the diagnostic procedures required for correct diagnosis. Accurate diagnosis and classification is required for proper treatment and counseling. Assessment of bleeding starts with the medical history. After a positive bleeding or family history, subsequent laboratory investigations will start with a panel of standard screening tests for hemostatic defects. Patients suspected of having VWD will be tested for plasma VWF antigen levels, the ability of VWF to bind platelets and FVIII activity. When VWD is confirmed, a set of subtyping tests can classify the patients as VWD types 1, 2 (A, B, M or N) or 3. The performance of some additional assays and analyses, such as VWF propeptide measurement or genetic analysis, may help in identifying the pathological mechanism behind certain defects or can guide in the choice of treatment.
© 2015 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  diagnosis; factor VIII; hemostasis; von Willebrand disease; von Willebrand factor

Mesh:

Substances:

Year:  2016        PMID: 26714181     DOI: 10.1111/jth.13243

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  11 in total

1.  A microfluidic model of hemostasis sensitive to platelet function and coagulation.

Authors:  R M Schoeman; K Rana; N Danes; M Lehmann; J A Di Paola; A L Fogelson; K Leiderman; K B Neeves
Journal:  Cell Mol Bioeng       Date:  2016-10-24       Impact factor: 2.321

2.  Preclinical evaluation of a semi-automated and rapid commercial electrophoresis assay for von Willebrand factor multimers.

Authors:  Marika Pikta; Galina Zemtsovskaja; Hector Bautista; Georges Nouadje; Timea Szanto; Margus Viigimaa; Valdas Banys
Journal:  J Clin Lab Anal       Date:  2018-02-17       Impact factor: 2.352

3.  ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease.

Authors:  Paula D James; Nathan T Connell; Barbara Ameer; Jorge Di Paola; Jeroen Eikenboom; Nicolas Giraud; Sandra Haberichter; Vicki Jacobs-Pratt; Barbara Konkle; Claire McLintock; Simon McRae; Robert R Montgomery; James S O'Donnell; Nikole Scappe; Robert Sidonio; Veronica H Flood; Nedaa Husainat; Mohamad A Kalot; Reem A Mustafa
Journal:  Blood Adv       Date:  2021-01-12

4.  Phenotypic and genetic characterizations of the Milan cohort of von Willebrand disease type 2.

Authors:  Omid Seidizadeh; Luciano Baronciani; Maria Teresa Pagliari; Giovanna Cozzi; Paola Colpani; Andrea Cairo; Simona Maria Siboni; Eugenia Biguzzi; Flora Peyvandi
Journal:  Blood Adv       Date:  2022-07-12

5.  Role of multimeric analysis of von Willebrand factor (VWF) in von Willebrand disease (VWD) diagnosis: Lessons from the PCM-EVW-ES Spanish project.

Authors:  Almudena Pérez-Rodríguez; Javier Batlle; Irene Corrales; Nina Borràs; Ángela Rodríguez-Trillo; Esther Lourés; Ana Rosa Cid; Santiago Bonanad; Noelia Cabrera; Andrés Moret; Rafael Parra; María Eva Mingot-Castellano; Nira Navarro; Carmen Altisent; Rocío Pérez-Montes; Shally Marcellini; Ana Moreto; Sonia Herrero; Inmaculada Soto; Nuria Fernández Mosteirín; Víctor Jiménez-Yuste; Nieves Alonso; Aurora de Andrés Jacob; Emilia Fontanes; Rosa Campos; María José Paloma; Nuria Bermejo; Rubén Berrueco; José Mateo; Karmele Arribalzaga; Pascual Marco; Ángeles Palomo; Nerea Castro Quismondo; Belén Iñigo; María Del Mar Nieto; Rosa Vidal; María Paz Martínez; Reyes Aguinaco; Maria Tenorio; María Ferreiro; Javier García-Frade; Ana María Rodríguez-Huerta; Jorge Cuesta; Ramón Rodríguez-González; Faustino García-Candel; Manuela Dobón; Carlos Aguilar; Fernando Batlle; Francisco Vidal; María Fernanda López-Fernández
Journal:  PLoS One       Date:  2018-06-20       Impact factor: 3.240

6.  Combination of acquired von Willebrand syndrome (AVWS) and Glanzmann thrombasthenia in monoclonal gammopathy of uncertain significance (MGUS), a case report.

Authors:  Elizabeth Sarah Mayne; Malcolm Tait; Barry Frank Jacobson; Evashin Pillay; Susan J Louw
Journal:  Thromb J       Date:  2018-11-26

7.  Potential Undiagnosed VWD Or Other Mucocutaneous Bleeding Disorder Cases Estimated From Private Medical Insurance Claims.

Authors:  Robert F Sidonio; Ayesha Zia; Dana Fallaize
Journal:  J Blood Med       Date:  2020-01-06

Review 8.  Obstacles to Early Diagnosis and Treatment of Inherited von Willebrand Disease: Current Perspectives.

Authors:  Giancarlo Castaman; Silvia Linari
Journal:  J Blood Med       Date:  2021-03-22

9.  Preoperative screening for bleeding disorders: A comprehensive laboratory assessment of clinical practice.

Authors:  Minka J Vries; Paola E van der Meijden; Gerhardus J Kuiper; Patricia J Nelemans; Rick J Wetzels; René G van Oerle; Marcus D Lancé; Hugo Ten Cate; Yvonne M Henskens
Journal:  Res Pract Thromb Haemost       Date:  2018-07-27

Review 10.  How I manage severe von Willebrand disease.

Authors:  Frank W G Leebeek; Ferdows Atiq
Journal:  Br J Haematol       Date:  2019-09-09       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.